MK-5108 (VX-689)是一种有效的ATP竞争性Aurora A激酶抑制剂，IC50值为0.064nM。
Cas No.:1010085-13-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
MK-5108 (VX-689) is a potent ATP-competitive inhibitor of Aurora A kinase with an IC50 value of 0.064nM [1]. MK-5108 induces G2/M accumulation and polyploidy in cells, and diminishes the expression of Aurora A kinase as well as the downstream of TACC3 and Plk1 [2]. MK-5108 has been widely used to inhibit the growth arrest and death of various cancer cells [3].
In vitro, MK-5108 treatment for 72 hours significantly inhibits the proliferation of H460 cells and A427 cells, with IC50 values of 0.25μM and 0.13μM, respectively[4]. Treatment with MK-5108 (0.4μM) in combination with trametinib (8nM) for 24 hours significantly induced cell cycle arrest in HCT116 cells and inhibited the expression of proteins related to the G1/S phase progression[5]. Treatment with MK-5108 (0.1μM) for 48 hours can induce autophagy in IMR-32 cells, as evidenced by the increased expression level of LC3A/B-II protein[6].
In vivo, MK-5108 treatment via intraperitoneal injection at a dose of 20mg/kg/day for 5 consecutive days significantly reduced renal fibrosis and collagen deposition in the unilateral ureteral obstruction (UUO) mouse model, and alleviated renal inflammation[7]. Administering MK-5108 (30mg/kg) orally twice daily for 12 consecutive days significantly inhibited the growth of xenograft tumors in SCID mice bearing HCT116 tumors[8].
References:
[1] Amin M, Minton S E, LoRusso P M, et al. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors[J]. Investigational new drugs, 2016, 34(1): 84-95.
[2] Chinn D C, Holland W S, Mack P C. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies[J]. Journal of cancer research and clinical oncology, 2014, 140(7): 1137-1149.
[3] Kretzner L, Scuto A, Claudia K, et al. Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels[J]. Blood, 2009, 114(22): 1690.
[4] Chinn D C, Holland W S, Mack P C. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies[J]. Journal of cancer research and clinical oncology, 2014, 140(7): 1137-1149.
[5] Sato M, Yamamoto Y, Moriwaki T, et al. Combination of AURKA inhibitor and MEK inhibitor strongly enhances G1 arrest and induces synergistic antitumor effect on KRAS or BRAF mutant colon cancer cells[J]. Biochemistry and Biophysics Reports, 2025, 43: 102073.
[6] Durbas M, Pabisz P, Wawak K, et al. GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells[J]. Apoptosis, 2018, 23(9): 492-511.
[7] Jiang M, Bai M, Xu S, et al. Blocking AURKA with MK-5108 attenuates renal fibrosis in chronic kidney disease[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2021, 1867(11): 166227.
[8] Shimomura T, Hasako S, Nakatsuru Y, et al. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel[J]. Molecular cancer therapeutics, 2010, 9(1): 157-166.
MK-5108 (VX-689)是一种有效的ATP竞争性Aurora A激酶抑制剂，IC50值为0.064nM[1]。MK-5108诱导细胞发生G2/M期积累和多倍体化，并减少Aurora A激酶及下游TACC3和Plk1的表达[2]。MK-5108已被广泛用于抑制多种癌细胞的生长停滞和死亡[3]。
在体外，MK-5108处理72小时显著抑制了H460细胞和A427细胞的增殖，IC50值分别为0.25μM和0.13μM[4]。MK-5108 (0.4μM) 联合trametinib (8nM) 处理HCT116细胞24小时，显著诱导了细胞周期阻滞，并抑制了与G1/S期进程相关的蛋白表达[5]。用MK-5108 (0.1μM) 处理IMR-32细胞48小时，可诱导细胞自噬，表现为LC3A/B-II蛋白表达水平升高[4]。
在体内，每日腹腔注射20mg/kg剂量的MK-5108，连续5天，显著减少了单侧输尿管梗阻（UUO）小鼠模型中的肾纤维化和胶原沉积，并减轻了肾脏炎症[7]。每日两次口服30mg/kg剂量的MK-5108，连续12天，显著抑制了携带HCT116肿瘤的SCID小鼠体内异种移植瘤的生长[8]。
| Cell experiment [1]: | |
Cell lines | H460 cells |
Preparation Method | H460 cells were maintained at 37°C in 5% CO2 in RPMI 1640 medium supplemented with 1×penicillin/streptomycin, 1×l-glutamine, 1×MEM vitamin solution, and 10% heat-inactivated fetal bovine serum (FBS). Cells were seeded at 1×103 cells/well in 96-well flat-bottom plates and allowed to attach overnight prior to treatment, and were treated with MK-5108 for 72h (0.01, 0.1, 1, 10, and 20µM). Then, analyze the cell viability. |
Reaction Conditions | 0.01, 0.1, 1, 10, and 20µM; 72h |
Applications | MK-5108 treatment significantly reduced cell viability of H460 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | SCID mice |
Preparation Method | SCID mice were kept in temperature-controlled (21°C-25°C) and humidity-maintained (40%-70%) rooms with a 12-h light/dark cycle. Water and food were provided freely. HCT116 cells were suspended in 50% Matrigel and 50% PBS, and s.c. transplanted into the side flank of SCID mice (1×107 cells/100μl). After 8 days, MK-5108 was suspended in 0.5% methyl cellulose/0.24% SDS (30mg/kg) and orally administered twice daily for 12 days. The volume (mm3) of each tumor was determined from the tumor diameter, which was measured with digital calipers using the following formula: tumor volume (mm3) = length×(width)2×0.5. |
Dosage form | 30mg/kg; twice a day for 12 days; p.o. |
Applications | MK-5108 treatment significantly inhibited the growth of xenograft tumors in SCID mice bearing HCT116 tumors. |
References: | |
| Cas No. | 1010085-13-8 | SDF | |
| 别名 | VX-689 | ||
| 化学名 | 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid | ||
| Canonical SMILES | C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O | ||
| 分子式 | C22H21ClFN3O3S | 分子量 | 461.94 |
| 溶解度 | ≥ 23.1 mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1648 mL | 10.8239 mL | 21.6478 mL |
| 5 mM | 433 μL | 2.1648 mL | 4.3296 mL |
| 10 mM | 216.5 μL | 1.0824 mL | 2.1648 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet